Partnership with SCINCO strengthens international sales and technical support channels in key region as part of ongoing global expansion

Cambridge, UK: CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced a strategic partnership with SCINCO, a specialist scientific instrument company based in South Korea. The agreement is the latest milestone in CN Bio’s international expansion, amplifying the Company’s presence in major Asian and Pacific markets and broadening access to its predictive human organ models.

Pharmaceutical and biotech companies are recognizing the potential of non-animal, new approach methodologies (NAMs) to improve preclinical efficacy and safety data generation in drug discovery and development workflows, leading to reduced failure rates of new drug candidates. In this pioneering field, the market is rapidly evolving in line with breaking regulatory developments, most recently the FDA announcing a shift toward human-relevant methods for drug development, replacing animal testing in the evaluation of monoclonal antibody therapies and other drugs¹.

Central to the Company’s ongoing growth strategy, CN Bio is establishing regional supply networks through specialist distribution partners to address growing demand for its FDA-recognized PhysioMimix^® OOC System and solutions. With the surge in South Korea’s biotech sector, driven by a series of billion-dollar licensing deals in early 2025 and the announcement of a new fund to support high-tech industries, the agreement with SCINCO uniquely positions CN Bio to support and expand operations in this high growth market. The partnership complements the Company’s wider network in the APAC region, including recently appointed Japanese distributor, Primetech².

CN Bio’s industry-leading benchtop PhysioMimix OOC range accurately mimics human physiology in the lab. Using advanced in vitro human organ models, these systems enable more accurate predictions of human drug responses to support the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal studies. These models provide insights into crucial aspects of preclinical drug development, including drug bioavailability, toxicology and disease modelling, providing information on how drugs will perform in patients and reduce the risk of costly late-stage failures in the clinic.

Soo Min Choi, Director, SCINCO: “Our dual-approach covering in-house development and the distribution of high-quality equipment from international manufacturers ensures we offer a comprehensive range of solutions to meet the diverse needs of all researchers, while leveraging unique insights to understand the scientific business landscape.” He added: “The global NAM market is growing at a rapid pace and to maintain the increased momentum across our industry, we believe adoption of these tools will become essential. We’re excited to be a part of the movement to bring CN Bio’s next-generation OOC solutions to the South Korean market.

Dr Paul Brooks, CEO, CN Bio: “Recent regulatory updates from the FDA are fueling a rapidly growing, global interest in human-relevant alternatives in drug development. Recognizing this, we are progressing an ambitious growth strategy to respond to market demand and put in place essential sales and support channels to ensure we remain ahead of the curve in addressing customers’ research needs. Partnering with SCINCO is an exciting development, allowing us to draw upon the team’s unique insights into the scientific and business landscape in South Korea to provide a strong footing as we expand further in the APAC region.”

1. https://cn-bio.com/important-fda-announcement/
2. Press release (13 January, 2025): CN-Bio Partners with Primetech to Distribute OOC Solutions

 Notes to Editors

About CN Bio cn-bio.com

CN Bio is on a mission to accelerate drug discovery. As a leading Organ-on-chip (OOC) company, the team is transforming how human-specific efficacy and safety data are generated.

CN Bio’s human organ models deepen the understanding of disease mechanisms, help uncover new drug targets and enable effective therapeutics to be developed safely. Throughout the discovery and development process, the Company’s portfolio of products and services help save time and reduce costs.

Based in Cambridge (UK), CN Bio brings over a decade of experience and know-how to engineering single and multi-organ microphysiological systems (MPS). As a result, the Company’s ground-breaking benchtop PhysioMimix^® OOC range can accurately mimic human physiology in the laboratory. Using advanced, predictive in vitro human organ models, these systems enable the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal models. These models also offer valuable insights into how drugs will perform in patients, greatly reducing risks in the clinic.

The power of PhysioMimix^® technology has been recognized by the US FDA, resulting in the first co- publication between a drug regulator and an MPS provider and has been harnessed by 13 of the leading pharmaceutical companies. In 2023, CN Bio helped deliver a regulatory world first, when the Company supported Inipharm’s INI-822 successful filing to initiate clinical testing for the treatment of metabolic liver disease treatment.

To find out more about CN Bio and how the Company is pioneering faster, more accurate drug discovery, please visit: cn-bio.com

About SCINCO scinco.com

SCINCO, a leading scientific instrument company based in South Korea, has carved a unique dual business model.

SCINCO excels not only in the development and export of in-house developed scientific instruments but also in the distribution of high-quality scientific equipment from international manufacturers.

This dual approach allows SCINCO to offer a comprehensive range of solutions to meet the diverse needs of its customers while leveraging unique insights to understand the scientific business landscape.

Whether as a supplier or distributor, SCINCO can provide the best solutions to meet the customers’ needs.

Over the last 30+ years, SCINCO has developed unique technologies and knowledge of scientific instruments.